Animal Pharm is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


Pfizer and Crucell in research license agreement

Dutch biotechnology company Crucell, developer of the proprietary PER.C6 production cell line technology, has signed a research license agreement with Pfizer Animal Health that will allow Pfizer to use the technology to develop a non-disclosed veterinary vaccine. Financial details of the deal were also not disclosed, but Crucell said that Pfizer had an option to commercialize the license. Spokespersons from both companies declined to comment further. The technology is used for the production of human and animal vaccines, antibodies, and gene therapies, among others; in December 2002, Crucell formed an alliance with DSM Biologics to expand manufacturing to therapeutic proteins and monoclonal antibodies. Crucell says that many of its pipeline products are based on its technology - these include vaccines for Ebola, West Nile virus, influenza, malaria, tuberculosis, and rabies.


What to read next




Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts